Sitagliptin Umbilical Cord Blood Transplant Study

Completed · Phase 2

Conditions studied: Leukemia, Myeloid, Acute, Acute Lymphoblastic Leukemia, Myelodysplasia, Leukemia, Myelogenous, Chronic, Lymphoma, Non-Hodgkin

In brief

The main purpose of this trial is to study whether the drug sitagliptin can be given safely to patients undergoing umbilical cord blood transplantation to speed up engraftment (recovery of blood counts after transplant).

Key facts

Study ID

NCT00862719

Run by

Indiana University

People needed

29

Starts

2009-03-01

Expected to finish

2015-02-01

Last updated by the study team

2016-10-07

Who can join

Age: 18 and older, up to 59. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients must have one of the following disease types with disease-specific features as outlined in the protocol:
• Acute myeloid leukemia (AML)
• Acute lymphoblastic leukemia (ALL)
• Myelodysplasia
• Chronic myelogenous leukemia
• Patients with aggressive non-Hodgkin's lymphoma (NHL), including diffuse large cell lymphoma, mediastinal B-cell lymphoma, transformed lymphoma, mantle cell lymphoma, and peripheral T cell lymphoma
• Hodgkin's lymphoma
• Relapsed Multiple Myeloma
• At least 35 days following start of preceding leukemia induction cytotoxic chemotherapy
• Patient age 18-55 years
• Karnofsky Performance status ≥ 70%
• No availability of a consenting HLA-matched related donor who is either matched fully matched or mismatched at only one locus of HLA-A, -B, and DRB1.
• No availability of a readily available HLA-matched volunteer unrelated donor (8 of 8 allele match at HLA-A, -B, -C and -DRB1). Patients with unstable disease who are in danger of significant disease progression while waiting to procure volunteer donor cells will be eligible to be treated on this protocol, even if a matched donor is available.
• Patients must have a matched or partially matched UCB unit with greater than 1.8 x10-7 nucleated cells/kg of recipient weight at the time of cryopreservation.
• No current uncontrolled bacterial, viral or fungal infection (defined as currently taking medication and progression of clinical symptoms).
• No HIV disease. Patients with immune dysfunction are at a significantly higher risk of infection from intensive immunosuppressive therapies.
• Non pregnant and non-nursing. Treatment under this protocol would expose a fetus to significant risks.
• Required baseline laboratory values as defined in the protocol

You may not qualify if…

• Symptomatic uncontrolled coronary artery disease or congestive heart failure.
• Severe hypoxemia with room air PaO2 less than 70, supplemental oxygen dependence, or DLCO less than 50 percent predicted
• Patients with central nervous system (CNS) involvement refractory to intrathecal chemotherapy
• Prior allogeneic or autologous hematopoietic stem cell transplant in the last 6 months

Where it is running

• IU Simon Cancer Center — Indianapolis, Indiana, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.